(L4-S1), s/p RT to calf tumor and L5, s/p cyclophosphamide + MTX, under screening for BLZ945 trial. Dr. 陳敬左. 台大醫院腫瘤醫學部. 10:55-11:55. Discussion.
確定! 回上一頁